Sanjivani Paranteral, HAL ink agreement to manufacture IV formulations & IV Sets
Sanjivani Paranteral Limited, a leading pharmaceutical company specialising in the manufacturing and distribution of high-quality parenteral and oral solid products, has inked a significant agreement with Hindustan Antibiotics Limited for the manufacturing of IV formulations and IV Sets. The agreement is backed by a confirmed purchase commitment from Hindustan Antibiotics Limited.
The partnership will see the establishment of a cutting-edge manufacturing facility within the premises of Hindustan Antibiotics Limited at Pimpri works, Pune, Maharashtra. Sanjivani Paranteral will soon initiate the process of upgrading facilities, the production is likely to start from Q3FY25. The plant capacity will be 50 lakh IV fluids bottles and 10 lakh IV sets per month. This strategic move underlines both companies' commitment to meet the demand of IV formulations and IV sets. The total investment for the project would be Rs. 50 crore.
"Our aim is to build a world-class organization grounded in Passion, Performance, and Partnership," said Ashwani Khemka, chairman & managing director of Sanjivani Paranteral Ltd. "Our collaboration with Hindustan Antibiotics Limited not only reaffirms our commitment to innovation and healthcare quality but also aligns with our vision for advancing pharmaceutical manufacturing in India. We believe that by contributing to 'Make in India,' we can significantly impact the evolution of IV formulations and IV Sets, ultimately benefiting patients and healthcare providers."
Speaking on the partnership, Milind Palhade from Hindustan Antibiotics Ltd, said, “This partnership epitomizes our commitment to fostering innovation and maintaining high-quality standards in the healthcare sector. We firmly believe that our combined capabilities will make a substantial contribution to the progression. The joint venture will help to elevate the standards of pharmaceutical manufacturing, emphasizing innovation, quality, and accessibility in the production of IV formulations and IV Sets. Both the companies are positive about the transformative impact this collaboration will have on healthcare delivery in India.”
Sanjivani Paranteral Limited is a pharmaceutical company headquartered in Mumbai, with manufacturing plants in Navi Mumbai and Dehradun. Operating in 25 countries, the company is 70% export-oriented and has more than 100 product approvals worldwide.
Hindustan Antibiotics Limited (HAL) is the first drug manufacturing company to be set up in the public sector by Government of India with active co-operation of WHO and UNICEF. Set up on 10th March, 1954, HAL is the first drug manufacturing unit in India to undertake commercial production of antibiotics like penicillin, streptomycin, gentamicin, ampicillin & amoxycillin etc.

Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!